Approval · Notice of Compliance 9410 · 2008
SIMVASA: Notice of Compliance 9410
Issued February 29, 2008
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9410
- Date
- February 29, 2008
- Company
- Paladin Labs Inc
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Therapeutic class
- Lipid metabolism regulator, platelet aggregation inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SIMVASA | 02305720 | — |
| SIMVASA | 02305739 | — |
| SIMVASA | 02305747 | — |
| SIMVASA | 02305755 | — |
| SIMVASA | 02305763 | — |
| SIMVASA | 02305771 | — |
| SIMVASA | 02305798 | — |
| SIMVASA | 02305801 | — |
| SIMVASA | 02305828 | — |
| SIMVASA | 02305836 | — |
| SIMVASA | 02305844 | — |
| SIMVASA | 02305852 | — |
| SIMVASA | 02305860 | — |
| SIMVASA | 02305879 | — |
| SIMVASA | 02305887 | — |
Medicinal ingredients
- SIMVASTATIN 5 MG per TAB
- ACETYLSALICYLIC ACID 81 MG per TAB
- SIMVASTATIN 10 MG per TAB
- SIMVASTATIN 20 MG per TAB
- SIMVASTATIN 40 MG per TAB
- SIMVASTATIN 80 MG per TAB
- ACETYLSALICYLIC ACID 162 MG per TAB
- ACETYLSALICYLIC ACID 325 MG per TAB